Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial

Conclusions
PF-04236921 was not significantly different from placebo for the primary efficacy end point in patients with SLE. Evidence of an effect with 10 mg was seen in a post hoc analysis. Safety was acceptable for doses up to 50 mg as the 200 mg dose was discontinued due to safety findings.

Trial registration number
NCT01405196; Pre-results.

Source: Annals of the Rheumatic Diseases - February 16, 2017 Category: Rheumatology Authors: Wallace, D. J., Strand, V., Merrill, J. T., Popa, S., Spindler, A. J., Eimon, A., Petri, M., Smolen, J. S., Wajdula, J., Christensen, J., Li, C., Diehl, A., Vincent, M. S., Beebe, J., Healey, P., Sridharan, S. Tags: Open access, Immunology (including allergy), Pain (neurology), Connective tissue disease, Systemic lupus erythematosus, Epidemiology Clinical and epidemiological research Source Type: research